SHENZHEN, China, Oct. 22 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the "Company") (HTDS.PK) www.htdsmedical.com,further to the company news release of August 26 2009, where amongst other things the company provided access to the U.S. Patent and Trademark Office ("USPTO") documents relating to intellectual property ("IP") ownership
HTDS management has officially notified the OTCBB company utilizing the IP rights rightfully belonging to HTDS and has placed the OTCBB company on legal notice of a pending lawsuit. HTDS intends to file shortly. HTDS brings attention to its shareholders of certain "Supplementary" filings "Legal Notice" made today with Pink Sheets. The information can be accessed at http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds and is self explanatory.
HTDS management is of the opinion that this information is material, and both issuers need to disclose its potential effect to its shareholders, followers and investors. The OTCBB company has made some remarks of this dispute in their filings with the SEC.
HTDS ownership rights for the five patents can be accessed at the following five USPTO websites:
Again as this is worth repeating, HTDS management and its advisors continue to monitor the situation and intend to vigorously escalate its claim to protect its IP interests. Moving forward, HTDS is not ruling out any available options at this point regarding the IP rights that may have a positive significant impact on the entire value of HTDS.
To continue receiving other HTDS updates which please register free at www.minamargroup.com/updates
Further updates to follow.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Global Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact firstname.lastname@example.org; for any corporate matters, please contact email@example.com, www.htdsmedical.com
SOURCE Hard to Treat Diseases
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All